Αποτελέσματα Αναζήτησης
Sharing Alzheimer’s research data with the world. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
- About
About - ADNI | Alzheimer's Disease Neuroimaging Initiative
- News & Publications
News & Publications - ADNI | Alzheimer's Disease...
- HELP / FAQ
HELP / FAQ - ADNI | Alzheimer's Disease Neuroimaging...
- About
22 Ιουλ 2015 · ! 2 PROTOCOL SYNOPSIS Title Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) Primary Objective The major goals of ADNI2 are to: 1. Determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s Disease (AD), as the pathology evolves from normal
Apply For Data Access. The application process includes acceptance of the Data Use Agreement and submission of an online application form. The application must include the investigator’s institutional affiliation and the proposed uses of the ADNI. Apply for Access through IDA. Application Review.
Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). [1] This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with ...
Alzheimer’s disease (AD), the most common form of dementia [1,2]. It is a complex progressive neurodegenerative disease that leads to the loss of memory and cognitive function.
31 Δεκ 2021 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, naturalistic study to understand structural, biochemical, and cognitive changes that occur during Alzheimer's disease (AD) progression.
Since its inception in 2004, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been advancing the standardized assessment of cognitive, clinical and biomarker measures of disease progression in cohorts of individuals who are clinically normal or have mild cognitive impairment or mild dementia.
